HER2 expression in carcinomas of the true cardia (siewert type II esophagogastric junction carcinoma)

World Journal of Surgery

Volumn 38, Issue 2, 2014, Pages 426-430

  Katai, Hitoshi ^a   Ishida, Michihiro ^a   Yamashita, Hiroharu ^a   Ohashi, Masaki ^a   Morita, Shinji ^a   Katayama, Hiroshi ^a   Fukagawa, Takeo ^a   Kushima, Ryoji ^a  

^a NATIONAL CANCER CENTER HOSPITAL   (Japan)

Author keywords

[No Author keywords available]

Indexed keywords

ANTINEOPLASTIC AGENT; EPIDERMAL GROWTH FACTOR RECEPTOR 2; MONOCLONAL ANTIBODY; TRASTUZUMAB;

ADENOCARCINOMA; ADJUVANT CHEMOTHERAPY; AGED; ARTICLE; CANCER STAGING; CARDIA; FEMALE; HUMAN; LIVER TUMOR; LOWER ESOPHAGUS SPHINCTER; MALE; METABOLISM; METASTASIS; MIDDLE AGED; MORTALITY; MULTIVARIATE ANALYSIS; PATHOLOGY; RETROSPECTIVE STUDY; STATISTICAL MODEL; STOMACH TUMOR; TUMOR INVASION; TUMOR RECURRENCE;

ADENOCARCINOMA; AGED; ANTIBODIES, MONOCLONAL, HUMANIZED; ANTINEOPLASTIC AGENTS; CARDIA; CHEMOTHERAPY, ADJUVANT; ESOPHAGOGASTRIC JUNCTION; FEMALE; HUMANS; LIVER NEOPLASMS; LOGISTIC MODELS; MALE; MIDDLE AGED; MULTIVARIATE ANALYSIS; NEOPLASM INVASIVENESS; NEOPLASM RECURRENCE, LOCAL; NEOPLASM STAGING; RECEPTOR, ERBB-2; RETROSPECTIVE STUDIES; STOMACH NEOPLASMS;

EID: 84893171353     PISSN: 03642313     EISSN: 14322323     Source Type: Journal    
DOI: 10.1007/s00268-013-2256-6     Document Type: Article

References (22)

1. Bang YJ, Van Cutsem E, Feyereislova A et al (2010) Trastuzumab in combination with chemotherapy versus chemotherapy alone for treatment of HER2-positive advanced gastric or gastro-oesophageal junction cancer (ToGA): a phase 3, open-label, randomised controlled trial. Lancet 376:687-697
2. Kusano C, Gotoda T, Khor CJ et al (2008) Changing trends in the proportion of adenocarcinoma of the esophagogastric junction in a large tertiary referral center in Japan. J Gastroenterol Hepatol 23:1662-1665
3. Yamashita H, Katai H, Morita S et al (2011) Optimal extent of lymph node dissection for Siewert type II esophagogastric junction carcinoma. Ann Surg 254:274-280
4. Siewert JR, Stein HJ (1996) Carcinoma of the gastroesophageal junction: classification, pathology and extent of resection. Dis Esophagus 9:173-182
5. Janjigian YY, Werner D, Pauligk C et al (2012) Prognosis of metastatic gastric and gastroesophageal junction cancer by HER2 status: a European and USA international collaborative analysis. Ann Oncol 23:2656-2662
6. Kataoka Y, Okabe H, Yoshizawa A et al (2013) HER2 expression and its clinicopathological features in resectable gastric cancer. Gastric Cancer 16:84-93
7. Gravalos C, Jimeno A (2008) HER2 in gastric cancer: a new prognostic factor and a novel therapeutic target. Ann Oncol 19:1523-1529
8. Bang Y, Chung J, Xu J, et al. (2009) Pathological features of advanced gastric cancer (GC): relationship to human epidermal growth factor receptor 2 (HER2) positivity in the global screening programme of the ToGA trial. J Clin Oncol (Meeting Abstracts) 27(Suppl 15):abstract 4556
9. Begnami MD, Fukuda E, Fregnani JH et al (2011) Prognostic implications of altered human epidermal growth factor receptors (HERs) in gastric carcinomas: HER2 and HER3 are predictors of poor outcome. J Clin Oncol 29:3030-3036
10. Kim KC, Koh YW, Chang HM et al (2011) Evaluation of HER2 protein expression in gastric carcinomas: comparative analysis of 1,414 cases of whole-tissue sections and 595 cases of tissue microarrays. Ann Surg Oncol 18:2833-2840
11. Ruschoff J, Hanna W, Bilous M et al (2012) HER2 testing in gastric cancer: a practical approach. Mod Pathol 25:637-650
12. Sobin LH, Gospodarowicz MK, Wittekind C (eds) (2009) TNM classification of malignant tumours, 7th edn. Wiley-Blackwell, Hoboken
13. Chua TC, Merrett ND (2012) Clinicopathologic factors associated with HER2-positive gastric cancer and its impact on survival outcomes: a systematic review. Int J Cancer 130:2845-2856
14. Terashima M, Kitada K, Ochiai A et al (2012) Impact of expression of human epidermal growth factor receptors EGFR and ERBB2 on survival in stage II/III gastric cancer. Clin Cancer Res 18:5992-6000
15. Park YS, Ryu M, Park HJ, et al. (2011) HER2 status as an independent prognostic marker in patients with advanced gastric cancer receiving adjuvant chemotherapy after curative gastrectomy. J Clin Oncol (Meeting Abstracts) 29(Suppl 15):abstract 4084
16. Park DI, Yun JW, Park JH et al (2006) HER-2/neu amplification is an independent prognostic factor in gastric cancer. Dig Dis Sci 51:1371-1379
17. Grabsch H, Sivakumar S, Gray S et al (2010) HER2 expression in gastric cancer: rare, heterogeneous and of no prognostic value - conclusions from 924 cases of two independent series. Cell Oncol 32:57-65
18. Sasano H, Date F, Imatani A et al (1993) Double immunostaining for c-erbB-2 and p53 in human stomach cancer cells. Hum Pathol 24:584-589
19. Slamon DJ, Clark GM, Wong SG et al (1987) Human breast cancer: correlation of relapse and survival with amplification of the HER-2/neu oncogene. Science 235:177-182
20. Slamon DJ, Godolphin W, Jones LA et al (1989) Studies of the HER-2/neu proto-oncogene in human breast and ovarian cancer. Science 244:707-712
21. Katai H, Maruyama K, Sasako M et al (1994) Mode of recurrence after gastric cancer surgery. Dig Surg 11:99-103
22. Ishida M, Morita S, Saka M et al (2012) Metachronous liver metastasis from early gastric cancer. J Gastrointest Surg 16:837-841